{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer&page=61",
    "query": {
      "condition": "Cancer",
      "page": 61
    },
    "page_size": 10
  },
  "pagination": {
    "page": 61,
    "page_size": 10,
    "total_count": 50362,
    "total_pages": 5037,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer&page=62&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cancer&page=60&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-31T12:00:37.188Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02489448",
      "title": "Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "MEDI4736",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 68,
      "start_date": "2015-11",
      "completion_date": "2021-08-02",
      "has_results": true,
      "last_update_posted_date": "2022-10-26",
      "last_synced_at": "2026-10-31T12:00:37.188Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02489448"
    },
    {
      "nct_id": "NCT05479578",
      "title": "Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Castration-Resistant Prostate Carcinoma",
        "Metastatic Prostate Adenocarcinoma",
        "Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) V8"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rashmi Verma, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 7,
      "start_date": "2022-06-29",
      "completion_date": "2025-05-01",
      "has_results": false,
      "last_update_posted_date": "2025-01-08",
      "last_synced_at": "2026-10-31T12:00:37.188Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05479578"
    },
    {
      "nct_id": "NCT00345826",
      "title": "Dasatinib in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "dasatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 19,
      "start_date": "2005-11",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-01-08",
      "last_synced_at": "2026-10-31T12:00:37.188Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00345826"
    },
    {
      "nct_id": "NCT05958485",
      "title": "A Close Examination of Patient Experiences in Glioblastoma Multiforme Clinical Research",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Glioblastoma Multiforme"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Power Life Sciences Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 500,
      "start_date": "2024-08",
      "completion_date": "2026-08",
      "has_results": false,
      "last_update_posted_date": "2023-07-24",
      "last_synced_at": "2026-10-31T12:00:37.188Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05958485"
    },
    {
      "nct_id": "NCT00474825",
      "title": "Dose Escalation Study of Hyperbaric Oxygen With Radiation and Chemotherapy to Treat Squamous Cell Carcinoma of the Head and Neck",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Carcinoma, Squamous Cell",
        "Cancer of the Head and Neck"
      ],
      "interventions": [
        {
          "name": "Hyperbaric Oxygen Therapy",
          "type": "DRUG"
        },
        {
          "name": "Hyperbaric oxygen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Baromedical Services",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 12,
      "start_date": "2007-07",
      "completion_date": "2011-02",
      "has_results": false,
      "last_update_posted_date": "2012-02-06",
      "last_synced_at": "2026-10-31T12:00:37.188Z",
      "location_count": 3,
      "location_summary": "Rochester, Minnesota • Lebanon, New Hampshire • Norfolk, Virginia",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        },
        {
          "city": "Norfolk",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00474825"
    },
    {
      "nct_id": "NCT01234025",
      "title": "Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Castrate-Resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "ISIS EIF4E Rx",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ionis Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 113,
      "start_date": "2010-11",
      "completion_date": "2013-12",
      "has_results": false,
      "last_update_posted_date": "2023-10-06",
      "last_synced_at": "2026-10-31T12:00:37.188Z",
      "location_count": 11,
      "location_summary": "Fayetteville, Arkansas • San Bernardino, California • Fort Collins, Colorado + 8 more",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "San Bernardino",
          "state": "California"
        },
        {
          "city": "Fort Collins",
          "state": "Colorado"
        },
        {
          "city": "Norwalk",
          "state": "Connecticut"
        },
        {
          "city": "Lakeland",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01234025"
    },
    {
      "nct_id": "NCT02301117",
      "title": "A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "TAS-102",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Taiho Oncology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2015-01",
      "completion_date": "2019-06-19",
      "has_results": false,
      "last_update_posted_date": "2024-09-05",
      "last_synced_at": "2026-10-31T12:00:37.188Z",
      "location_count": 10,
      "location_summary": "Phoenix, Arizona • Duarte, California • Santa Monica, California + 6 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02301117"
    },
    {
      "nct_id": "NCT03761017",
      "title": "MGD019 DART® Protein in Unresectable/Metastatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Squamous Cell Non Small Cell Lung Cancer",
        "Prostate Cancer Metastatic",
        "Cutaneous Melanoma",
        "Colorectal Cancer",
        "Advanced Cancer",
        "Solid Tumor, Adult"
      ],
      "interventions": [
        {
          "name": "Lorigerlimab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "MacroGenics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 162,
      "start_date": "2018-12-12",
      "completion_date": "2025-01-27",
      "has_results": false,
      "last_update_posted_date": "2025-03-06",
      "last_synced_at": "2026-10-31T12:00:37.188Z",
      "location_count": 17,
      "location_summary": "Chicago, Illinois • Boston, Massachusetts • Grand Rapids, Michigan + 11 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03761017"
    },
    {
      "nct_id": "NCT00005617",
      "title": "Vaccine Therapy in Treating Patients With Stage IV or Relapsed Malignant Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "dendritic cell-MART-1 peptide vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "leukapheresis",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "1997-07",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2020-08-03",
      "last_synced_at": "2026-10-31T12:00:37.188Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005617"
    },
    {
      "nct_id": "NCT07869368",
      "title": "BLinatumomab and iNKT in Relapsed B-Cell ALL",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "B-Cell ALL",
        "ALL (Acute B-Lymphoblastic Leukemia)",
        "Philadelphia Chromosome-Negative Lymphoblastic Leukemia",
        "CD19-positive B-cell Acute"
      ],
      "interventions": [
        {
          "name": "Invariant Natural Killer T Cell Therapy",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2026-10",
      "completion_date": "2030-02",
      "has_results": false,
      "last_update_posted_date": "2026-10-09",
      "last_synced_at": "2026-10-31T12:00:37.188Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07869368"
    }
  ]
}